advertisement
Wei Y 23
Showing records 1 to 23 | Display all abstracts from Wei Y104977 A New Contact Lens Sensor System for Continuous Intraocular Pressure Monitoring: Evaluation of Safety and Tolerability
Zhang Y
Eye Contact Lens 2022; 48: 439-444
104797 The application and progression of CRISPR/Cas9 technology in ophthalmological diseases
Hu X
Eye 2023; 37: 607-617
104949 Efficacy and safety of netarsudil/latanoprost fixed-dose combination vs. monotherapy in open-angle glaucoma or ocular hypertension: A systematic review and meta-analysis of randomized controlled trials
Luo N
Frontiers in medicine 2022; 9: 923308
104797 The application and progression of CRISPR/Cas9 technology in ophthalmological diseases
Zhang B
Eye 2023; 37: 607-617
104977 A New Contact Lens Sensor System for Continuous Intraocular Pressure Monitoring: Evaluation of Safety and Tolerability
Wei Y
Eye Contact Lens 2022; 48: 439-444
104949 Efficacy and safety of netarsudil/latanoprost fixed-dose combination vs. monotherapy in open-angle glaucoma or ocular hypertension: A systematic review and meta-analysis of randomized controlled trials
Jiang X; Hao M
Frontiers in medicine 2022; 9: 923308
104797 The application and progression of CRISPR/Cas9 technology in ophthalmological diseases
Li X
Eye 2023; 37: 607-617
104977 A New Contact Lens Sensor System for Continuous Intraocular Pressure Monitoring: Evaluation of Safety and Tolerability
Karunaratne IK; Lee CHC
Eye Contact Lens 2022; 48: 439-444
104949 Efficacy and safety of netarsudil/latanoprost fixed-dose combination vs. monotherapy in open-angle glaucoma or ocular hypertension: A systematic review and meta-analysis of randomized controlled trials
Fang Z
Frontiers in medicine 2022; 9: 923308
104797 The application and progression of CRISPR/Cas9 technology in ophthalmological diseases
Li M
Eye 2023; 37: 607-617
104977 A New Contact Lens Sensor System for Continuous Intraocular Pressure Monitoring: Evaluation of Safety and Tolerability
Deng M
Eye Contact Lens 2022; 48: 439-444
104949 Efficacy and safety of netarsudil/latanoprost fixed-dose combination vs. monotherapy in open-angle glaucoma or ocular hypertension: A systematic review and meta-analysis of randomized controlled trials
Wei Y
Frontiers in medicine 2022; 9: 923308
104797 The application and progression of CRISPR/Cas9 technology in ophthalmological diseases
Wang Y
Eye 2023; 37: 607-617
104977 A New Contact Lens Sensor System for Continuous Intraocular Pressure Monitoring: Evaluation of Safety and Tolerability
Chen Z
Eye Contact Lens 2022; 48: 439-444
104797 The application and progression of CRISPR/Cas9 technology in ophthalmological diseases
Dan H
Eye 2023; 37: 607-617
104949 Efficacy and safety of netarsudil/latanoprost fixed-dose combination vs. monotherapy in open-angle glaucoma or ocular hypertension: A systematic review and meta-analysis of randomized controlled trials
Zhang W
Frontiers in medicine 2022; 9: 923308
104797 The application and progression of CRISPR/Cas9 technology in ophthalmological diseases
Zhou J
Eye 2023; 37: 607-617
104977 A New Contact Lens Sensor System for Continuous Intraocular Pressure Monitoring: Evaluation of Safety and Tolerability
Yang Y; Chong IT
Eye Contact Lens 2022; 48: 439-444
104797 The application and progression of CRISPR/Cas9 technology in ophthalmological diseases
Wei Y
Eye 2023; 37: 607-617
104977 A New Contact Lens Sensor System for Continuous Intraocular Pressure Monitoring: Evaluation of Safety and Tolerability
Chong IT; Lam DCC; Lam DCC
Eye Contact Lens 2022; 48: 439-444
104797 The application and progression of CRISPR/Cas9 technology in ophthalmological diseases
Ge K
Eye 2023; 37: 607-617
104977 A New Contact Lens Sensor System for Continuous Intraocular Pressure Monitoring: Evaluation of Safety and Tolerability
Yu M
Eye Contact Lens 2022; 48: 439-444
104797 The application and progression of CRISPR/Cas9 technology in ophthalmological diseases
Li P; Song Z
Eye 2023; 37: 607-617
